Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Laboratorios Farmaceuticos Rovi SA (Rovi), a subsidiary of Norbel Inversiones SL, is a pharmaceutical company that carries out the research, development, manufacturing, and marketing of prescription and hospital products. The company's product portfolio includes licensed prescription pharmaceuticals in the therapeutic areas of cardiovascular, osteoarticular, thrombosis, pneumology, gynecology, central nervous system (CNS), endocrinology, oncology, and urology; diagnostic imaging products include contrast agents and injection systems for imaging procedures such as computed tomography, X-rays, magnetic resonance imaging and ultrasound screening; products for the care and maintenance of venous and arterial catheters. It markets its products in Italy, the UK, Austria, Ireland, Hungary, Poland, Spain, Portugal and others. Rovi is headquartered in Madrid, Spain.
Headquarters
Spain
Address
Calle Jose Isbert, 2 - Pozuelo de Alarcon, Madrid, 28223
Website
www.rovi.es
Telephone
34 91 213000
No of Employees
2,111
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ROVI (MCE)
Revenue (2022)
$897.1M
1.4%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-14.7%
(2022 vs 2021)
Market Cap*
$4.8B
Net Profit Margin (2022)
XYZ
-15.9%
(2022 vs 2021)
* As of and is in US$
Laboratorios Farmaceuticos Rovi SA premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Prescription Medicines | Rovi |
| Hospital | Hibor |
| Diagnostic Imaging and Catheter Care Products | Osseor |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In March, the company signed an agreement with Insud Pharma and Innvierte Economia Sostenible SICC, SME, S.A. to establish a company. |
| 2022 | New Products/Services | In November, the company launched an initiative to develop solutions to improve sustained release injectable drug delivery technologies. |
| 2022 | Contracts/Agreements | In May, the company cooperated with Youhua Biotechnology to obtain agency rights in Taiwan and Hong Kong for European-approved long-acting injections to treat adult patients with schizophrenia. |
Competitor Comparison
| Key Parameters | Laboratorios Farmaceuticos Rovi SA | Grifols SA | Almirall SA | Grupo Ferrer Internacional SA | Faes Farma SA |
|---|---|---|---|---|---|
| Headquarters | Spain | Spain | Spain | Spain | Spain |
| City | Madrid | Barcelona | Barcelona | Barcelona | Madrid |
| State/Province | Madrid | Barcelona | - | Barcelona | Madrid |
| No. of Employees | 2,111 | 23,744 | 1,904 | 1,861 | 1,748 |
| Entity Type | Public | Public | Public | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Juan Lopez-Belmonte Lopez | Chief Executive Officer; Director; President | Executive Board | - | - |
| Ivan Lopez-Belmonte Encina | Director; Vice President | Executive Board | - | - |
| Javier Lopez-Belmonte Encina | Director; Vice President | Executive Board | - | - |
| Gabriel Nunez Fernandez | Secretary | Senior Management | - | - |
| Ignacio Zarzalejos Toledano | Deputy Secretary | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer